LDL lowering effect of PCSK9 inhibition is reduced in women
Eur Heart J Cardiovasc Pharmacother
6 Aprile Apr 2023 2 months ago
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of plasma low-density lipoprotein cholesterol (LDL-C) concentration and its inhibition reduces the risk of atherosclerotic cardiovascular disease (ASCVD). We aimed to assess the sex-differential effect of either pharmacological or genetic inhibition of PCSK9 on LDL-C levels.
Reference: LDL lowering effect of PCSK9 inhibition is reduced in women.
Myasoedova VA, Rimbert A, Camera M, Le May C, Capoulade R, Cariou B, Poggio P. Eur Heart J Cardiovasc Pharmacother. 2023 Jan 31:pvad009.